NKTR (Nektar Therapeutics) Forward P/E Multiple

Corporate company logo of Nektar (NKTR)

Nektar Therapeutics (NKTR) revenues rely on counterparty milestone payments for progress in developing immunotherapies and license royalties. The company's forward P/E ratio confirms this trend, with 0.00 serving as the current metric level. Green chemistry principles dictate an environmentally friendly approach to substance disposal, while equipment modernization at production sites ensures there is no capacity depreciation.

Projected Price to Earnings: Nektar Therapeutics Inc. (NKTR) for 07/04/2022 - 11/17/2026

Analytical breakdowns for Nektar Therapeutics

- current price and projected stock value:
Summary company analytics:nektar.com
Product sample of Nektar Therapeutics

Assessing the fundamental value of Nektar Therapeutics (NKTR) requires an analysis of market expectations regarding future earnings. This ratio compares the current share price to the projected earnings per share. The trend in the issuer's forward P/E reflects a shift in investor sentiment concerning capital efficiency. For Nektar Therapeutics (NKTR), this indicator captures market confidence in the success of new immuno-oncology developments. A decline in this metric would confirm the effectiveness of cost restructuring against the backdrop of existing cash reserves.

Competitors of Nektar Therapeutics (NKTR)

Projected Price to Earnings ARGX (Argenx)|BNTX (BioNTech Group) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (Abivax SA)|Market Cap to Projected Earnings admabiologics.com (ADMA)|PTGX - Future Price to Earnings|Immunovant Inc (IMVT) - Projected Price to Earnings|Kiniksa Corp (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols, S.A.|Projected Price to Earnings ADPT|Forward P/E Multiple celldex.com|Future Price to Earnings Aurinia Pharma (AUPH)|BioCryst Pharmaceuticals - Price to Future Earnings Ratio|Forward P/E Multiple VERA (veratx.com)|Dianthus Pharma (DNTH) - Projected Price to Earnings Ratio|PHVS - Future Price to Earnings|ABCL - Forward P/E Multiple|Tourmaline (TRML) - Future Price to Earnings|Precigen - Future Price to Earnings Multiple|PHAR (Pharming Group NV) - Forward P/E Multiple|UPB (Upstream Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ZBIO|Forward P/E Multiple immunome.com (IMNM)|Forward P/E Multiple GOSS (gossamerbio.com)|Market Cap to Projected Earnings KalVista Pharma (KALV)|SEPN - Future Price to Earnings|Market Cap to Projected Earnings Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Projected Price to Earnings|Price to Expected Earnings Ratio RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - Forward P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Future Price to Earnings engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Future Price to Earnings Multiple|Aerovate Therapeutics - Projected Price to Earnings|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics, Inc - Forward P/E Multiple|Price to Expected Earnings Ratio TLSA|CABA: Forward P/E Multiple|Projected Price to Earnings Ventyx Bio|Future Price to Earnings Theratechnologies, Inc.|Projected Price to Earnings Ratio Avalo Therapeutics AVTX|Forward P/E Multiple ELDN|AGEN (Agenus, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|adagene.com (ADAG) - Projected Price to Earnings|Ikena Oncology (IMA) - Future Price to Earnings|Projected Price to Earnings Shattuck Labs, Inc.|Future Price to Earnings equilliumbio.com|Projected Price to Earnings connectbiopharm.com (CNTB)|Forward P/E Multiple IMUX|Market Cap to Projected Earnings Atara Bio|Future Price to Earnings InflaRx N.V. IFRX|X4 Pharmaceuticals - Future Price to Earnings|ACET: Projected Price to Earnings|Future Price to Earnings Multiple CELU (celularity.com)|INMB: Forward P/E Multiple|BRNS: Market Cap to Future Earnings Ratio|KZR (Kezar Life Sciences, Inc.) - Forward P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Market Cap to Projected Earnings|Forward P/E Multiple AKTX|Future Price to Earnings ENLV (Enlivex Therapeutics Ltd)|Future Price to Earnings Q32 Bio Inc. QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|Projected Price to Earnings Ratio iBio|CARM: Forward P/E Multiple|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals, Ltd.)|Future Price to Earnings boltbio.com|Forward P/E Multiple HCW Biologics|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt Inc.)|Market Cap to Projected Earnings GRI Bio, Inc. (GRI)|XRTX - Future Price to Earnings|reshapelifesciences.com (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple